Table 1.
Sandostatin LAR | TACE | multimodal therapy | palliative care | ||||||
---|---|---|---|---|---|---|---|---|---|
BCLC A | BCLC B | BCLC A | BCLC B | BCLC A | BCLC B | BCLC A | BCLC B | ||
number | 11 | 14 | 5 | 9 | 7 | 10 | 17 | 22 | |
Sex | |||||||||
male | 6 | 10 | 4 | 8 | 7 | 9 | 14 | 16 | |
female | 5 | 4 | 1 | 1 | 0 | 1 | 3 | 6 | |
liver cirrhosis | |||||||||
no | 0 | 0 | 0 | 2 | 1 | 0 | 2 | 2 | |
yes | 11 | 14 | 5 | 7 | 6 | 10 | 15 | 20 | |
Child-Pugh-classification | |||||||||
Child A | 9 | 12 | 1 | 3 | 5 | 8 | 7 | 7 | |
Child B | 2 | 2 | 4 | 4 | 1 | 2 | 8 | 13 | |
Child C | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
MELD (median/range) | 7.33 (0.27-15.98) | 7.61 (0.16-15.0) | 14.60 (11.13-17.35) | 11.46 (6.68-16.90) | 11.56 (6.78-49.26) | 8.98 (7.15-16.01) | 12.31 (4.66-58.20) | 13.20 (1.53-49.82) | |
Etiology | |||||||||
Alcoholism | 5 | 8 | 2 | 4 | 5 | 3 | 8 | 8 | |
chronic hepatitis B | 1 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | |
chronic hepatitis C | 4 | 4 | 3 | 2 | 1 | 7 | 5 | 7 | |
others | 1 | 2 | 0 | 3 | 0 | 0 | 2 | 6 | |
Age (median/range) | 66.5 (53.7-80.5) | 68.7 (49.4-73.4) | 64.9 (63.6-69.2) | 68.4 (48.4-78.4) | 50.5 (47.4-64.6) | 69.9 (61.2-76.9) | 68.5 (43.1-81.2) | 62.5 (44.8-73.4) |